|
MechanismGnRHR antagonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date12 Apr 1999 |
100 Clinical Results associated with Merck Serono Europe Ltd.
0 Patents (Medical) associated with Merck Serono Europe Ltd.
100 Deals associated with Merck Serono Europe Ltd.
100 Translational Medicine associated with Merck Serono Europe Ltd.